INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.930
0.00 (0.00%)
At close: Oct 2, 2026, 4:00 PM EDT
1.935
+0.005 (0.26%)
After-hours: Oct 2, 2026, 7:30 PM EDT
INmune Bio Revenue
In the year 2025, INmune Bio had annual revenue of $50.00K with 257.14% growth.
Revenue (ttm)
$50.00K
Revenue Growth
+257.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
53.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.00K | 36.00K | 257.14% |
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Apollomics | 8.84M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
| Mereo BioPharma Group | 500.00K |
| Clene | 197.00K |
| Serina Therapeutics | 130.00K |
| eXoZymes | -700.00 |
INMB News
- 18 days ago - INmune Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 18 days ago - INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board - GlobeNewsWire
- 23 days ago - INmune Bio to Present at the H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 5 weeks ago - INmune Bio submits two regulatory packages to EMA for Ebstrocel - TheFly
- 5 weeks ago - INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings - GlobeNewsWire
- 1 month ago - INmune Bio Earnings Call Transcript: Q2 2026 - Transcripts
- 1 month ago - INmune Bio Quarterly report: Q2 2026 - Filings
- 1 month ago - INmune Bio Earnings release: Q2 2026 - Filings